Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Nuvalent, a clinical-stage biopharmaceutical company (Nasdaq: NUVL), has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 5, 2024, at 1:05 p.m. ET in New York City.
Key details:
- CEO James Porter, Ph.D., and CFO Alexandra Balcom will participate in a fireside chat
- A live webcast will be available on the company's website
- The webcast will be archived for 30 days after the presentation
Nuvalent focuses on developing precisely targeted therapies for clinically proven kinase targets in cancer. This conference participation provides an opportunity for investors and stakeholders to gain insights into the company's progress and future plans.
Nuvalent, un'azienda biofarmaceutica in fase clinica (Nasdaq: NUVL), ha annunciato la sua partecipazione al 22° Congresso Globale Annuale sulla Salute di Morgan Stanley. L'evento si svolgerà il 5 settembre 2024, alle 13:05 ET a New York City.
Dettagli chiave:
- Il CEO James Porter, Ph.D., e il CFO Alexandra Balcom parteciperanno a una conversazione informale
- Una diretta web sarà disponibile sul sito dell'azienda
- La registrazione della diretta sarà archiviata per 30 giorni dopo la presentazione
Nuvalent si concentra sullo sviluppo di terapie mirate con precisione per obiettivi chinasici clinicamente provati nel cancro. La partecipazione a questo congresso offre l'opportunità agli investitori e agli stakeholder di ottenere informazioni sui progressi e sui piani futuri dell'azienda.
Nuvalent, una compañía biofarmacéutica en etapa clínica (Nasdaq: NUVL), ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. El evento se llevará a cabo el 5 de septiembre de 2024, a la 1:05 p.m. ET en la ciudad de Nueva York.
Detalles clave:
- El CEO James Porter, Ph.D., y la CFO Alexandra Balcom participarán en una charla informal
- Se podrá acceder a una transmisión en vivo en el sitio web de la compañía
- La transmisión se archivará durante 30 días después de la presentación
Nuvalent se centra en desarrollar terapias dirigidas de manera precisa para objetivos de quinasas clínicamente comprobados en el cáncer. La participación en esta conferencia ofrece a los inversores y partes interesadas la oportunidad de obtener información sobre los avances y planes futuros de la empresa.
Nuvalent, 임상 단계의 생명공학 회사 (Nasdaq: NUVL), 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 5일 오후 1시 5분 ET 뉴욕시에서 열립니다.
주요 내용:
- CEO James Porter 박사와 CFO Alexandra Balcom이 대화에 참여합니다
- 회사의 웹사이트에서 생중계가 제공됩니다
- 발표 후 30일 동안 웹캐스트가 아카이브됩니다
Nuvalent는 암에서 임상적으로 입증된 키나아제 표적에 대해 정밀하게 조준된 치료법을 개발하는 데 중점을 두고 있습니다. 이번 컨퍼런스 참가를 통해 투자자와 이해관계자들은 회사의 진행 상황과 향후 계획에 대한 통찰을 얻을 수 있는 기회를 가집니다.
Nuvalent, une société bio-pharmaceutique en phase clinique (Nasdaq: NUVL), a annoncé sa participation à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. L'événement aura lieu le 5 septembre 2024, à 13h05 ET à New York.
Détails clés :
- Le PDG James Porter, Ph.D., et la CFO Alexandra Balcom participeront à une discussion informelle
- Une diffusion en direct sera disponible sur le site de l'entreprise
- La diffusion sera archivée pendant 30 jours après la présentation
Nuvalent se concentre sur le développement de thérapies ciblées de manière précise pour des cibles de kinases cliniquement prouvées dans le cancer. La participation à cette conférence offre aux investisseurs et aux parties prenantes l'opportunité d'obtenir des informations sur les progrès et les plans futurs de l'entreprise.
Nuvalent, ein biopharmazeutisches Unternehmen in klinischer Phase (Nasdaq: NUVL), hat seine Teilnahme an der 22. Jahrestagung für globales Gesundheitswesen von Morgan Stanley angekündigt. Die Veranstaltung findet am 5. September 2024 um 13:05 Uhr ET in New York City statt.
Wichtige Details:
- Der CEO James Porter, Ph.D., und die CFO Alexandra Balcom werden an einem Fireside-Chat teilnehmen
- Ein Live-Stream wird auf der Website des Unternehmens verfügbar sein
- Der Webcast wird 30 Tage nach der Präsentation archiviert
Nuvalent konzentriert sich auf die Entwicklung präzise zielgerichteter Therapien für klinisch bewährte Kinaseziele im Krebsbereich. Die Teilnahme an dieser Konferenz bietet Investoren und Interessengruppen die Möglichkeit, Einblicke in die Fortschritte und zukünftigen Pläne des Unternehmens zu gewinnen.
- None.
- None.
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference-302233283.html
SOURCE Nuvalent, Inc.
FAQ
When is Nuvalent (NUVL) participating in the Morgan Stanley Healthcare Conference?
Who will represent Nuvalent (NUVL) at the Morgan Stanley Healthcare Conference?
How can I watch Nuvalent's (NUVL) presentation at the Morgan Stanley Healthcare Conference?
What is the focus of Nuvalent's (NUVL) research and development?
